Response
TO LITHIUM NETWORK
Patients included in all centres
Primary Goals
Bipolar disorder (BD) is a highly prevalent mental disorder and a leading cause of suicide. Lithium is the primary pharmacological treatment for the prevention of new bipolar disorder episodes or relapses.
Collaborative Research Project
Summary of the project
Optimizing response to lithium treatment through personalized evaluation of individuals with bipolar I disorder: the R-LiNK initiative
This project has received funding from The European Union’s Horizon 2020 Research and Innovation programme Under Grant Agreement N° 754907
Prof. Frank Bellivier, MD, PhD
Department of Psychiatry and Addiction Medicine - Expert Centres Paris Diderot University
INSERM UMR-S1144
frank.bellivier@inserm.fr
Hôpital Fernand Widal 200, rue du Faubourg Saint-Denis 75475 Paris Cedex10. France
Tel Office: +33 1 40 05 42 25 / Tel Assistant: +33 1 40 05 48 69